

## Editor-in-Chief Search for the Journal of Clinical and Translational Science

The Journal of Clinical and Translational Science (JCTS) is accepting applications for the position of Editor-in-Chief. The current editor of the JCTS will be stepping down at the end of the calendar year.

All candidates for the position of Editor-in-Chief (EIC) of the Journal of Clinical and Translational Science are asked to respond to the [candidate questionnaire](#) and provide a curriculum vitae to [info@actscience.org](mailto:info@actscience.org) by July 31, 2019.

Please visit the [ACTS Website](#) for more information. For additional information about the JCTS, candidates are welcome to contact JCTS Editor-in-Chief George Mashour ([gmashour@med.umich.edu](mailto:gmashour@med.umich.edu)) and ACTS Publications Committee Chair Barry Collier ([collerb@mail.rockefeller.edu](mailto:collerb@mail.rockefeller.edu)).

## Letter From the JCTS Editor

### Diversity in Translation

Diversity is of critical importance to the translational process. Ensuring that diverse and under-represented populations are included in research is essential for the downstream effectiveness and successful implementation of interventions that serve broad populations. Newly published articles in JCTS—which can be accessed through the [FirstView](#) tab—address some dimensions of diversity in translation. Jennifer Cunningham-Erves and colleagues identify [racial differences in two measures of trust in biomedical research](#), underscoring the need for thoughtful approaches to community engagement and recruitment. As examples of this, Alka Kanaya and team report a comparison of techniques for successfully [recruiting and retaining US South Asians](#) in epidemiologic research, while Yiyang Liu et al. demonstrate that [Asian Americans are less willing to engage in health-related research](#) than other racial groups, but this is not due to differential levels of trust. Collectively, these newly published studies highlight the complexities of diversity in translational research and motivate further investigation. JCTS commends these authors for their work, we are proud to have been the home for their exciting studies, and we encourage more such submissions to ensure that the clinical and translational science community is effectively “translating” in many diverse languages so that research serves all of society.



## Journal of Clinical and Translational Science



**Volume 2 / Issue 6** of the Journal of Clinical and Translational Science is available online!

JCTS's mission is to provide a forum for the rapid communication of topics of interest and relevance to the large and diverse community of clinical and translational scientists with the goal of improving the efficiency with which health needs inform research and new diagnostics, therapies, and preventive measures reach the public. The Association for Clinical and Translational Science has partnered with the American Physician Scientists Association (APSA) and the Clinical Research Forum (CRF) to support the growth and development of JCTS.

**Submit your article today to be featured in future issues of JCTS!** Please also visit the [JCTS website](#) for information on our themed issues related to Dissemination and Implementation as well as Rural Health.

## News From the Hill

### News From the Hill: June 21, 2019

The House continues to outpace the Senate in the effort to advance appropriations bills for Fiscal Year (FY) 2020. Recently, the House of Representatives passed a package of spending measure dubbed “minibus 1”, which includes the annual Labor-HHS-Education (LHHS), Defense, State and Foreign Operations, and Energy and Water bills.



Following passage of minibus 1, the House quickly turned its attention to “minibus 2”, which includes the Agriculture-FDA, the Veterans Administration, Interior and Environment, Commerce-Justice-Science, and Transportation-Housing-Urban Development.

See the full newsletter on the [ACTS Advocacy page](#).

## Translational Science Today



## NIH launches large TB prevention trial for people...

A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the...

[Read more](#)  
[www.nih.gov](http://www.nih.gov)

---

Do you know someone who deserves to be recognized for outstanding or groundbreaking work? Send ACTS your story to be highlighted in future versions of ACTS Connection. **Submit stories to: [info@actscience.org](mailto:info@actscience.org).**

[Website](#) [About Us](#) [Advocacy](#) [News & Publications](#) [Annual Meeting](#)

Association for Clinical and Translational Science  
2025 M St NW Suite 800  
Washington, DC 20036  
(202) 367 1119  
[info@actscience.org](mailto:info@actscience.org)  
[www.actscience.org](http://www.actscience.org)

